<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100630</url>
  </required_header>
  <id_info>
    <org_study_id>CN001-023</org_study_id>
    <nct_id>NCT03100630</nct_id>
  </id_info>
  <brief_title>Compare Bioavailability of BMS-986089 After Subcutaneous Injection</brief_title>
  <official_title>An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BMS-986089 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study in healthy men and women. Assess the similarity of BMS-986089 when injected
      into the arm, thigh, or the stomach. Collect data on safety of BMS-986089.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to time of last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events ( AEs)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram findings</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physical examination findings</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinical laboratory test findings</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: BMS-986089</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMS-986089 subcutaneous injections on specified days; abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: BMS-986089</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMS-986089 subcutaneous injections on specified days; arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: BMS-986089</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMS-986089 subcutaneous injections on specified days; thigh</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986089</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Treatment A: BMS-986089</arm_group_label>
    <arm_group_label>Treatment B: BMS-986089</arm_group_label>
    <arm_group_label>Treatment C: BMS-986089</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participant as determined by no significant deviations in normal medical and
             surgical history and assessments

          -  Body Mass Index 18 kg/m2 to 32 kg/m2

          -  females must be of non-childbearing potential

        Exclusion Criteria:

          -  tattoos or other skin findings on any of the potential injection sites

          -  history of chronic muscle pain within 30 days prior to study treatment

          -  prior history of IgG1 therapy

        Other protocol defined inclusion and exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. if there is no contact information, please email:</last_name>
    <email>clinical.trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and site #</last_name>
  </overall_contact_backup>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>March 29, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
